Furthermore, studies of insulin treatment in animals and clinical trials of intranasal insulin administration in individuals with AD have indicated that intranasal insulin not only improves memory but also reduces inflammation and white matter hyperintensities (Reger et al., 2006; Craft et al., 2012; Chang et al., 2021; Kellar et al., 2021). This evidence concerns the gene INS and Alzheimer disease.